Multiple Myeloma: Bone Pain, Anemia, and What Testing May Show

Multiple myeloma is a cancer of plasma cells, a type of white blood cell found in bone marrow. It may lead to bone pain, anemia, frequent infections, kidney problems, and characteristic changes on blood, urine, and imaging tests.

Overview

Multiple myeloma is a cancer that develops in plasma cells. Plasma cells are part of the immune system and normally help the body fight infection by making antibodies. In multiple myeloma, abnormal plasma cells grow in the bone marrow and produce large amounts of one abnormal antibody, often called a monoclonal protein or M protein.

As these cells build up, they can crowd out healthy blood-forming cells in the marrow. This may reduce the production of red blood cells, white blood cells, and platelets. The disease can also affect the bones, kidneys, and immune system, which is why symptoms may seem unrelated at first.

Some people are diagnosed after symptoms appear, while others learn they have myeloma because routine bloodwork shows unusual protein levels, anemia, or kidney changes. There is also a related earlier stage called smoldering myeloma, in which abnormal plasma cells are present but there are no signs of organ damage. Because several plasma cell disorders can look similar, doctors usually assess myeloma alongside conditions such as leukemia and other bone marrow diseases during evaluation.

Symptoms and What Patients May Notice

Symptoms of multiple myeloma can vary widely. Bone pain is one of the best-known signs, especially in the back, ribs, hips, or shoulders. This happens because myeloma can weaken bones and increase the risk of fractures. Some people notice persistent pain, while others first seek help after a fracture occurs with minimal injury.

Fatigue is also common and is often related to anemia, which means there are not enough healthy red blood cells to carry oxygen effectively. Anemia may cause tiredness, weakness, shortness of breath with activity, dizziness, or looking pale. Because these symptoms are common in many conditions, they may develop gradually and be mistaken for normal aging or stress.

Other possible symptoms include repeated infections, unexplained weight loss, increased thirst, constipation, confusion, numbness or tingling, and reduced urine output. Not everyone has all of these features. Some people have no obvious symptoms at first, and the condition is discovered during testing for abnormal protein, kidney function changes, or unexplained bone findings.

• Bone pain or fractures
• Fatigue and weakness from anemia
• Frequent or severe infections
• Kidney-related problems
• Symptoms linked to high calcium, such as thirst or constipation

Causes and Risk Factors

The exact cause of multiple myeloma is not fully understood. It begins when a plasma cell develops genetic changes that allow it to grow and survive longer than it should. Over time, these abnormal cells multiply inside the bone marrow. In most cases, there is no single event a patient can identify as the direct cause.

Doctors do know that some factors are linked with a higher chance of developing the disease. Risk increases with age, and multiple myeloma is more often diagnosed in older adults. A personal history of monoclonal gammopathy of undetermined significance, often called MGUS, or smoldering myeloma can increase the likelihood of progressing to active disease. Family history may play a role in some people.

Certain environmental and occupational exposures have been studied, but they do not explain most cases. It is important for patients to know that multiple myeloma is not contagious and is not caused by everyday contact with others. Having risk factors does not mean a person will definitely develop the disease, and many people diagnosed have no clear risk factor apart from age.

What Testing May Show

When doctors suspect multiple myeloma, testing usually begins with blood and urine studies. Blood tests may show anemia, high calcium levels, abnormal kidney function, or a raised total protein level. Specialized tests can detect the M protein and measure free light chains, which are fragments of antibodies made by abnormal plasma cells. These results help doctors understand whether the plasma cells are producing excess abnormal protein and how active the disease may be.

Urine testing can also be important because some patients pass abnormal light chains into the urine. These proteins can sometimes contribute to kidney damage. A 24-hour urine collection or other urine protein tests may be used to assess how much abnormal protein is present and whether the kidneys are under strain.

Imaging is used to look for bone involvement. Depending on the situation, doctors may recommend X-rays, low-dose whole-body CT, MRI, or PET-CT to look for bone thinning, small destructive lesions, fractures, or areas of active disease. A bone marrow biopsy is often needed to confirm the diagnosis. This test examines a sample of marrow for the number and appearance of plasma cells and may include genetic and molecular studies that help guide prognosis and treatment planning.

Because the diagnosis rests on both laboratory and organ-related findings, doctors look for evidence of myeloma-related damage such as anemia, kidney impairment, high calcium, or bone lesions. If a hematology team needs broader staging and evaluation, it may include advanced testing and imaging similar to specialized blood tests and laboratory services and PET-CT imaging as part of the workup.

How Multiple Myeloma Is Diagnosed and Staged

A diagnosis of multiple myeloma is made by combining symptoms, examination findings, lab results, imaging, and bone marrow analysis. Doctors distinguish active multiple myeloma from MGUS and smoldering myeloma because treatment needs differ. Active myeloma usually means the abnormal plasma cells are causing clear health problems or there are test features that strongly predict imminent progression.

Staging helps estimate how advanced the disease is and supports treatment planning. Doctors often use blood markers such as beta-2 microglobulin, albumin, lactate dehydrogenase, and specific genetic changes found in myeloma cells. These findings do not define a person’s future with certainty, but they help the care team choose an appropriate approach and discuss outlook in a realistic, individualized way.

In addition to staging the disease, clinicians also assess kidney health, bone strength, infection risk, nerve symptoms, and overall fitness. This broad assessment matters because two people with the same diagnosis may need different treatment plans depending on age, daily functioning, and other medical conditions.

Treatment Options

Treatment depends on whether the disease is active, how quickly it is progressing, the patient’s symptoms, and overall health. People with MGUS or smoldering myeloma may not need treatment right away, but they do need regular monitoring. Active multiple myeloma is usually treated with a combination of medicines designed to control abnormal plasma cells, reduce complications, and improve quality of life.

Common treatment categories include targeted therapies, immunomodulatory medicines, corticosteroids, and in some cases monoclonal antibodies or other newer immune-based approaches. Some patients may be candidates for high-dose chemotherapy followed by bone marrow transplant, also called stem cell transplant, which can be an important part of treatment for selected individuals.

Supportive care is just as important as anti-myeloma treatment. This may include medicines to strengthen bones, fluids and monitoring to protect the kidneys, pain control, infection prevention, and treatment for anemia. Radiation therapy may be used to relieve pain or treat a specific bone area at risk, and surgery may sometimes be needed for fractures or spinal instability. When cancer-directed therapy is being planned, care may be coordinated through medical oncology and, when appropriate, radiation oncology.

Treatment is usually tailored over time because myeloma can behave differently from one person to another. Some people respond well for long periods, while others need changes in therapy if the disease returns or becomes resistant. A clear follow-up plan and regular monitoring are central parts of good care.

Prevention, Self-care, and Living With Myeloma

There is no proven way to prevent multiple myeloma. However, early evaluation of persistent bone pain, unexplained anemia, recurrent infections, or abnormal protein tests may help lead to diagnosis before more serious complications develop. People who have MGUS or smoldering myeloma should keep regular follow-up appointments so any change can be detected promptly.

Self-care focuses on protecting general health and reducing complications. Staying well hydrated may support kidney health, especially if a doctor has advised this. Patients are often encouraged to avoid medicines or supplements that may strain the kidneys unless approved by their care team. Gentle physical activity, when safe, can support strength and mobility, but heavy lifting or high-impact activity may not be appropriate if the bones are fragile.

Good infection prevention is also important because myeloma and some of its treatments can weaken the immune system. This may include hand hygiene, staying up to date with recommended vaccines after medical advice, and reporting fevers or infection symptoms promptly. Nutrition, rest, emotional support, and pain management all play valuable roles in day-to-day wellbeing.

Near the end of the treatment journey, some patients seek care at centers with coordinated hematology, oncology, imaging, and transplant services. Acibadem International’s multidisciplinary specialists in JCI-accredited hospitals diagnose and treat multiple myeloma for international patients, with care plans tailored to the individual’s condition and overall health.

When to See a Doctor

A person should consider medical evaluation if there is persistent bone pain, unusual fatigue, repeated infections, unexplained weight loss, or symptoms such as increased thirst, constipation, or weakness that do not improve. These symptoms do not always mean multiple myeloma, but they do deserve attention, especially if they continue or worsen.

Urgent medical assessment is important if there is sudden severe back pain, a suspected fracture, confusion, very reduced urine output, or signs of serious infection such as fever with chills. These problems can sometimes reflect complications that need prompt treatment. People already diagnosed with multiple myeloma should contact their care team if they notice new pain, numbness, worsening fatigue, or changes in kidney function or hydration.

Because the condition can affect several body systems, early review by a qualified doctor or hematologist is often helpful. A timely diagnosis can clarify the cause of symptoms and allow the care team to discuss monitoring, supportive care, or treatment options in a structured and reassuring way.

Frequently asked questions

What is multiple myeloma?

Multiple myeloma is a cancer of plasma cells, which are immune cells made in the bone marrow. The abnormal cells can build up in the marrow, make an unusual antibody protein, and affect bones, blood counts, kidneys, and immunity.

Is bone pain always present in multiple myeloma?

No. Bone pain is common, but not every person has it at diagnosis. Some people first learn they have multiple myeloma because blood or urine tests are abnormal, or because they have anemia, kidney problems, or repeated infections.

How is multiple myeloma confirmed?

Doctors usually confirm the diagnosis with a combination of blood tests, urine tests, imaging studies, and a bone marrow biopsy. These tests help show whether abnormal plasma cells are present and whether they are causing organ or bone damage.

Can multiple myeloma be cured?

Multiple myeloma is often treatable for long periods, but it is generally considered a chronic relapsing disease rather than a condition that is always permanently cured. Many people can achieve remission or good disease control with modern therapies and careful follow-up.

What is the difference between MGUS, smoldering myeloma, and active myeloma?

MGUS and smoldering myeloma are earlier plasma cell conditions that may not cause symptoms or organ damage. Active multiple myeloma means the disease is causing health problems or has features that strongly suggest it is about to do so, which is why treatment is usually recommended.

Does multiple myeloma affect the kidneys?

Yes, it can. Abnormal proteins made by myeloma cells may damage the kidneys, and other factors such as dehydration or high calcium can add to the problem. Kidney function is an important part of both diagnosis and ongoing treatment monitoring.

References

• World Health Organization
• National Cancer Institute
• American Cancer Society
• International Myeloma Foundation
• National Comprehensive Cancer Network

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.